FDA Approves Swallowable Balloon for Weight Loss: A New Option to GLP-1s
The U.S. Food and Drug Administration has approved a novel approach to weight loss: a swallowable gastric balloon. The Allurion Gastric Balloon System, designed for adults aged 22 to 65 with obesity, received premarket approval this week, offering a non-surgical alternative to existing weight management options, the company announced Monday.
The device consists of a capsule containing a deflated balloon that is swallowed by the patient. Once in the stomach, a physician fills the balloon with saline solution, causing it to expand and occupy space within the digestive system. This creates a feeling of fullness, intended to help individuals consume less food. According to Allurion Technologies, patients using the system can expect to lose approximately 14% of their body weight, with potential for greater loss through repeated use.
“This device expands our tool kit in treating obesity,” said Dr. Rabindra Watson, director of the metabolic health program at Cedars-Sinai Medicine in Los Angeles, who has been involved in the product’s development. “Even in the era of highly effective GLP-1 medications, there remains a substantial group of patients who either cannot tolerate these drugs, do not wish to accept a long-term injectable medication, lose access [to the GLP-1s] because of cost or insurance barriers, or prefer a time-limited intervention.”
Unlike other gastric balloons currently on the market, the Allurion system does not require endoscopy, surgery, or sedation for either placement or removal. The balloon is designed to deflate and pass naturally through the digestive system after approximately four months. “The actual administration of the capsule, which is about the size of a fish oil pill, takes about 15 minutes,” explained Shantanu Gaur, founder and CEO of Allurion Technologies. “When the balloon is done filling, the patient gets up, and leaves. The whole process is highly smooth, convenient, and quick.”
The approval is based on data from the AUDACITY trial, a multicenter, randomized study evaluating the safety and efficacy of the Allurion Gastric Balloon in adults with obesity. The system is intended for individuals with a body mass index (BMI) between 30 and 40 who have previously attempted weight loss programs without sustained success. Yale New Haven Health System medical director of bariatric surgery, Dr. John Morton, emphasized the importance of this requirement, stating, “You want to make sure that people are committed to having some sort of lifestyle changes, and that they understand how to deal with volume of food, how to orient themselves to protein instead of carbs, and how important exercise is for weight maintenance.” The treatment also includes six months of nutritional coaching.
The Allurion balloon has already been used in over 70 countries, including Canada, Mexico, and throughout Europe. Data from more than 30 peer-reviewed medical journal publications suggest patients can achieve over 20% weight loss with two balloon cycles. Rohit Sons, medical director of bariatric surgery at Temple University Hospital in Philadelphia, highlighted the convenience of the system, noting, “The fact that the balloon basically disintegrates and takes care of itself is a massive advantage. You don’t have to go back to a doctor’s office and have it pulled out.”
Potential side effects include temporary pressure, nausea, or stomach cramping in the days following placement. More serious, though uncommon, complications can include balloon migration, intestinal obstruction, or early deflation. Dr. Watson explained that the saline solution is mixed with a small amount of blue dye to provide an early warning system should deflation occur, allowing patients to seek medical attention.
While clinical trials indicate patients maintain 95% of their weight loss one year after the balloon passes through the system, Dr. Morton cautioned that long-term weight management remains a challenge. He noted that bariatric surgery currently offers the highest success rate for sustained weight loss.
Allurion Technologies anticipates the primary challenge following FDA approval will be training physicians on the proper use of the technology and establishing access points for interested patients. The company estimates the cost of the treatment to be comparable to GLP-1 medications, approximately $400 per month, but insurance coverage remains uncertain. “The reality is, most of the GLP-1 market right now is not covered by insurance — people are paying out of pocket, so that’s becoming a bit of the status quo here in the United States when it comes to weight loss,” Gaur said.